AAAAAA
Results:
1-13
|
Results: 13
Authors:
Gulbrandsen, N
Wisloff, F
Brinch, L
Carlson, K
Dahl, IM
Gimsing, P
Hippe, E
Hjorth, M
Knudsen, LM
Lamvik, J
Lenhoff, S
Lofvenberg, E
Nesthus, I
Nielsen, JL
Turesson, L
Westin, J
Citation: N. Gulbrandsen et al., Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support, MED ONCOL, 18(1), 2001, pp. 65-77
Authors:
Gulbrandsen, N
Wisloff, F
Nord, E
Lenhoff, S
Hjorth, M
Westin, J
Citation: N. Gulbrandsen et al., Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma, EUR J HAEMA, 66(5), 2001, pp. 328-336
Authors:
Jacobsen, EM
Barna-Cler, L
Taylor, JM
Triplett, DA
Wisloff, F
Citation: Em. Jacobsen et al., The evaluation of clotting times in the laboratory detection of lupus anticoagulants, THROMB RES, 104(4), 2001, pp. 275-282
Authors:
Jacobsen, EM
Barna-Cler, L
Taylor, JM
Triplett, DA
Wisloff, F
Citation: Em. Jacobsen et al., The Lupus Ratio test - An interlaboratory study on the detection of lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test - From the Fifth International Survey of Lupus Anticoagulants - ISLA 5, THROMB HAEM, 83(5), 2000, pp. 704-708
Authors:
Wisloff, F
Gulbrandsen, N
Citation: F. Wisloff et N. Gulbrandsen, Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients, ACTA ONCOL, 39(7), 2000, pp. 809-813
Authors:
Lenhoff, S
Hjorth, M
Holmberg, E
Turesson, I
Westin, J
Nielsen, JL
Wisloff, F
Brinch, L
Carlson, K
Carlson, M
Dahl, IM
Gimsing, P
Hippe, E
Johnsen, H
Lamvik, J
Lofvenberg, E
Nesthus, I
Rodjer, S
Citation: S. Lenhoff et al., Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study, BLOOD, 95(1), 2000, pp. 7-11
Authors:
Wisloff, F
Gulbrandsen, N
Nord, E
Citation: F. Wisloff et al., Therapeutic options in the treatment of multiple myeloma - Pharmacoeconomic and quality-of-life considerations, PHARMACOECO, 16(4), 1999, pp. 329-341
Authors:
Ringdal, K
Ringdal, GI
Kaasa, S
Bjordal, K
Wisloff, F
Sundstrom, S
Hjermstad, MJ
Citation: K. Ringdal et al., Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model, QUAL LIFE R, 8(1-2), 1999, pp. 25-43
Authors:
Hjorth, M
Holmberg, E
Rodjer, S
Turesson, I
Westin, J
Wisloff, F
Citation: M. Hjorth et al., Survival in conventionally treated younger (< 60 years) multiple myeloma patients: no improvement during two decades, EUR J HAEMA, 62(4), 1999, pp. 271-277
Authors:
Jacobsen, EM
Sandset, PM
Wisloff, F
Citation: Em. Jacobsen et al., Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?, THROMB RES, 94(4), 1999, pp. 213-220
Authors:
Turesson, I
Abildgaard, N
Ahlgren, T
Dahl, IM
Holmberg, E
Hjorth, M
Nielsen, JL
Oden, A
Seidel, C
Waage, A
Westin, J
Wisloff, F
Citation: I. Turesson et al., Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors, BR J HAEM, 106(4), 1999, pp. 1005-1012
Authors:
Stead, ML
Brown, JM
Velikova, G
Kaasa, S
Wisloff, F
Child, JA
Hippe, E
Hjorth, M
Sezer, O
Selby, P
Citation: Ml. Stead et al., Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma, BR J HAEM, 104(3), 1999, pp. 605-611
Authors:
Schjetlein, R
Abdelnoor, M
Haugen, G
Husby, H
Sandset, PM
Wisloff, F
Citation: R. Schjetlein et al., Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia, ACT OBST SC, 78(3), 1999, pp. 191-197
Risultati:
1-13
|